Recent studies have shown that lung cancer with increased YES1 was more responsive to Dasatinib (44), and increased expression of YES1 was reported to be one of the acquired resistant mechanisms to EGFR inhibitors in lung cancer with EGFR mutations (45). This evidence concerns the gene EGFR and lung cancer.